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Abstract Increasing evidence has shown that the brain is a
site of diabetic end-organ damage. This study investigates
cerebral metabolism and the interactions between astrocytes
and neurons at different stages of diabetes to identify the
potential pathogenesis of diabetic encephalopathy. [1-13C]glu-
cose or [2-13C]acetate is infused into 1- and 15-week diabetic
rats, the brain extracts of which are analyzed by using 1H and
13C magnetic resonance spectroscopy. The 13C-labeling pat-
tern and enrichment of cerebral metabolites are also investi-
gated. The increased 13C incorporation in the glutamine, glu-
tamate, and γ-aminobutyric acid carbons from [2-13C]acetate
suggests that the astrocytic mitochondrial metabolism is en-
hanced in 1-week diabetic rats. By contrast, the decreased
labeling from [1-13C]glucose reflected that the neuronal mi-
tochondrial metabolism is impaired. As diabetes developed to
15 weeks, glutamine and glutamate concentrations signifi-
cantly decreased. The increased labeling of glutamine C4
but unchanged labeling of glutamate C4 from [2-13C]acetate
suggests decreased astrocyte supply to the neurons. In addition,
the enhanced pyruvate recycling pathway manifested by the in-
creased lactate C2 enrichment in 1-week diabetic rats is weakened
in 15-week diabetic rats. Our study demonstrates the overall
metabolism disturbances, changes in specific metabolic pathways,
and interaction between astrocytes and neurons during the onset
and development of diabetes. These results contribute to the
mechanistic understanding of diabetes pathogenesis and evolution.
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Abbreviations
DM Diabetes mellitus
NAA N-acetyl aspartate
m-Ins Myo-inositol
1H NMR Proton nuclear magnetic resonance
Cho Choline
LDH Lactate dehydrogenase
PDH Pyruvate dehydrogenase
PC Pyruvate carboxylase
MCA Monocarboxylic acid
GS Glutamine synthetase
Glu Glutamate
Gln Glutamine
TCA Tricarboxylic acid
ALAT Alanine aminotransferase
Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder char-
acterized by hyperglycemia resulting from defects in insulin
secretion, insulin resistance, or both [1]. DM can result in
various complications, including retinopathy, nephropathy,
and peripheral neuropathy. The relationship between diabetes
and cognitive dysfunction has been first recognized in 1922
[2]. Such condition has been later designated as “diabetic
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encephalopathy” in 1950 [3]. Many studies have indicated
that diabetes affects the brain [4, 5]. Pathological researches
have observed significant progressive neuronal losses in the
hippocampus in type 1 diabetic rats [6, 7]. Studies using
magnetic resonance imaging techniques have identified ab-
normal white matter structure and function as well as reduced
gray matter volume and density in diabetic patients [8, 9]. All
these abnormalities are closely related to brain metabolic
disorders [10]. For example, decreased N-acetyl aspartate
(NAA) [11] and increased myo-inositol (m-Ins) [12] concen-
trations have been observed in the white matter of individuals
with diabetes by using localized proton nuclear magnetic
resonance (1H NMR). In addition, streptozotocin (STZ)-in-
duced diabetic rats exhibited increased cerebral lactate/choline
(Lac/Cho) ratio [13]. Analysis on metabolic derangement-
related enzymes have shown increased activity of lactate
dehydrogenase (LDH) [14] but decreased activity of pyruvate
dehydrogenase (PDH) and glutamine synthetase (GS) [15] in
the brains of alloxan-induced diabetic rats. Most previous
studies focused on determining the individual metabolites or
metabolism-related enzymes, but only few facilitated a com-
prehensive understanding of DM-associated metabolic char-
acteristics. In particular, the specific metabolic pathways di-
rectly related to the development of diabetic encephalopathy
are poorly understood.
Astrocytes have crucial functions in the brain, including
absorbing and disposing glutamate (Glu) from the synaptic
cleft, maintaining pH and appropriate concentrations of K+
and other ions in the interstitial milieu, and providing energy
substrates for neurons [16]. Increased astrocyte-specific glial
fibrillary acidic protein (GFAP) expression has been found in
the cortex and hippocampus of STZ-induced diabetic rats
[17]. In addition, Glu uptake has been decreased in the brain
[18], whereas neurotransmitter homeostasis has been impaired
in the hippocampus [19]. These functions and changes in the
neurotransmitter cycles between astrocytic and neuronal com-
partments in diabetic brain have not yet been reported.
The administration of 13C-labeled substrates combined
with 13C magnetic resonance spectroscopy (MRS) is a pow-
erful tool to detect 13C incorporation into different metabo-
lites. Sparse isotopic labeling using [1-13C]glucose or
[2-13C]acetate results in specific carbon positions within the
same metabolites and thus provides site-specific information.
These positions include tricarboxylic acid (TCA) cycle inter-
mediates and amino acids. As a result, the fate of 13C label can
be determined through multiple metabolic pathways in the
brain under different physiological and pathophysiological
conditions [20]. 13CMRS has successfully revealed decreased
Glu neurotransmission and impaired TCA cycle in patients
with Alzheimer’s disease [21]. Decreased glutamine (Gln)
supply to gamma-aminobutyric acid (GABA)ergic neurons
has been observed in the cortex and subcortex of young
epileptic rats, whereas astrocytic metabolism has been
increased in adult epileptic rats [22]. Mason et al. applied
[2-13C]acetate as a tracer to evaluate the hypothesis that pa-
tients with type 1 diabetes exhibit increased blood–brain
transport and monocarboxylic acid (MCA) metabolism to
sustain upregulated MCA transporters during hypoglycemia
[23].
13C MRS is a primary technique for studying brain metab-
olism. Glucose is metabolized primarily in the neurons,
whereas acetate is a well-known astrocyte-specific substrate.
The neuronal–glial metabolism and the interaction of their
compartments in the state of diabetes can be investigated
through the injection of 13C-labeled glucose and acetate. In
this study, the specific 13C-labeled location and labeled abun-
dance after substrate injection were measured in 1- and 15-
week diabetic rats, as well as in their age-matched controls.
The results demonstrated the comprehensive metabolism dis-
turbances and the changes in specific metabolic pathways in
the generation and development of diabetes, which provide
deep insights of pathogenesis and evolution of diabetes.
Materials and Methods
Animal Preparation and Infusion Techniques
Male Sprague–Dawley rats weighing 220±15 g (8 weeks of
age) are purchased from the SLAC Laboratory Animal Co.
Ltd. Shanghai, China, and are kept in a specific pathogen-free
colony of the Laboratory Animal Center of WenzhouMedical
University (Wenzhou, China) with regulated temperature and
humidity and a 12:12-h light–dark cycle with lights on at
8:00 a.m. During the whole experimental process, rats are
fed with certified standard rat chow and tap water ad libitum.
All animal treatments are strictly in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Four groups of rats are used (n=20∼28 for each group),
including diabetic 1-week, diabetic 15-week, and two age-
matched control groups. It should be mentioned that every
group of rats at each time point were randomly divided into
four subgroups. After a 12-h fast, rats are randomly selected
and injected intraperitoneally with STZ (Sigma-Aldrich),
which is prepared freshly in citrate buffer (0.1 M, pH 4.5) at
a single dosage of 70mg/kg body weight, whereas control rats
are injected with the same volume of vehicle. Two days after
STZ administration, the blood glucose concentrations are
measured and the rats of which higher than 16.70 mmol/L
are defined as diabetic rats.
Prior to each experiment, the rats are fasted overnight
(12 h) but had free access to water. The animals are anesthe-
tized, and the left jugular veins are dissected and cannulated
for infusion of the labeled or unlabeled substrates. During the
whole procedure, rats are kept under a glow lamp to maintain
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rectal temperature in the range of 36.8∼37.5 °C. As for unla-
beled or [1-13C]glucose (enriched at 99 %, 0.75 M), it is
infused at a continuous rate of 0.11 mL/kg per min while
unlabeled or [2-13C]acetate (enriched at 99 %, 1.5 M) is
infused at a constant rate of 0.18 mL/kg per min. The rats are
sacrificed by decapitation at the end of the infusion, and the
brains (whole brain minus cerebellum) are immediately re-
moved from the skull within 15 s and frozen in liquid nitrogen.
Brain Metabolite Extraction
The frozen cerebral tissue is weighed and put into a centrifuge
tube. Ice-cold methanol (4 mL/g) and distilled water
(0.85 mL/g) are added into the tube, homogenized at 4 °C
after thawing, and mixed by vortex. Chloroform (2 mL/g) and
distilled water (2 mL/g) are added into the tube and mixed
again. After the sample tube is kept on ice for 15 min, the
homogenate is centrifuged at 1,000 g for 15 min at 4 °C. The
supernatant is extracted and lyophilized for about 24 h. The
obtained aqueous extracts were then dissolved in 550 μL of
99.5 % D2O for NMR spectroscopy.
Acquisition of 1H and 13C NMR Spectra
High-resolution 1H and 13C NMR spectra of brain extracts are
carried out at 298 K on a Bruker AVANCE III 600-MHzNMR
spectrometer operating at 600.13 (H) and 150.92 (C) MHz,
respectively. 1H NMR spectra of brain extracts are acquired
using a 90° flip angle with a spectral width of 9,615 Hz and
64 K data points. The number of scans is 64, and an additional
10 s relaxation delay is used to ensure full relaxation. The
spectra are corrected manually for phase and baseline and
referenced to the chemical shift of the Lac methyl peaks at
1.33 ppm. An inverse-gated decoupling sequence
(INVGATE) is used for 13C experiments to avoid the Nuclear
Overhauser effect, and spectra are accumulated using a 30°
flip angle with a spectral width of 33,333 Hz and 64 K data
points. The acquisition time is 1 s, and an additional delay of
2 s is used to achieve fully relaxed conditions for each carbon
resonance. A total of 32,768 scans are accumulated for each
spectrum.
Data and Statistical Analysis
The specific 13C-enrichment of metabolites is calculated as
previously described [24, 25]. Metabolite contents (mmol/kg
wet weight) are determined relative to the concentration of
creatine (assumed to be 9 mmol/kg) from fully relaxed 1H
NMR spectra of brain extracts [26]. All values are expressed
as mean±SEM. Statistical comparisons between the experi-
mental groups are performed by independent samples t test. A
calculated value of p<0.05 is considered to be statistically
significant.
Results
1H NMR Data of Cerebral Metabolite
The representative 1H NMR spectra of the brain extracts
obtained from the rats in the control and diabetic groups
(1 week and 15 weeks of diabetes) are shown in Fig. 1a–c.
The resonances in Fig. 1a are unambiguously assigned from
our published work [27] and confirmed here in 2D 1H-1H
COSY and TOCSY spectra (data not shown). Endogenous
metabolites, such as Lac (δ1.33), alanine (Ala, δ1.46), NAA
(δ2.01), GABA (δ2.28), Glu (δ2.34), succinate (Suc, δ2.40),
Gln (δ2.46), aspartate (Asp, δ2.82), taurine (Tau, δ3.42), and
m-Ins (δ3.53), were simultaneously measured through the 1H
NMR spectra of the brain tissue extracts.
The concentrations of themetabolites measured in the brain
of 1- and 15-week diabetic rats and their age-matched controls
are summarized in Table 1. No changes are observed in the
metabolite concentrations in the brain of 1-week diabetic rats,
except for a decrease in NAA. By contrast, most metabolites
evidently changed in the 15-week diabetic group. Interesting-
ly, the neurotransmitter concentrations of Glu and Gln are
significantly decreased, whereas that of m-Ins is significantly
increased. The concentration of NAA is remarkably decreased
in the 15-week diabetic group.
13C NMR Spectra of [2-13C]Acetate Metabolism
The representative high-resolution 13C NMR spectra of the
brain extracts obtained from the rats infused with unlabeled
acetate or [2-13C]acetate are presented in Fig. 2a–c. The NMR
peaks in Fig. 2b have been previously assigned [28]. The 13C
NMR spectra in Fig. 2a obtained from the rats infused with
unlabeled acetate exhibited low peak sensitivity due to low
natural abundance. 13C NMR spectra with [2-13C]acetate me-
tabolism (Fig. 2b, c) show that the 13C isotope has been
successfully incorporated into the specific carbon sites of a
given metabolite, such as Gln, Glu, GABA, and Lac.
Interaction between neurons and astrocytes can be revealed
by analyzing the labeled patterns of the neurotransmitters.
Figure 3a, b demonstrates the site-specific 13C-enrichment of
Gln, Glu, and GABA in the C4, C3, and C2 carbons derived
from [2-13C]acetate. Each metabolite in the brains of 1- or 15-
week diabetic rats was evidently marked. The labeling abun-
dance is higher in Gln than in Glu, suggesting that the exog-
enous acetate can be metabolized as a glial-specific substrate.
For 1-week diabetic rats, the 13C labeling percentage in Gln
has increased, and all carbon positions are obtained compared
with those in the control (C4, 32.15±1.53 vs 23.77±1.39, p=
0.007; C3, 12.40±0.39 vs 9.35±0.60, p=0.005; and C2,
15.13±0.57 vs 11.63±0.63, p=0.006). 13C-enrichment in
the C4 position of Glu has significantly increased (14.60±
0.63 vs 12.27±0.59, p=0.035). Moreover, the 13C-label
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incorporation into the C2 and C3 positions showed a clear
increasing trend compared with that of the age-matched con-
trol. The 13C-enrichment of GABA has remarkably increased
in the C2 position (12.89±0.50 vs 10.14±0.72, p=0.021) but
remained constant in the C3 and C4 positions. As diabetes
developed to 15 weeks, the 13C-enrichment of Gln, Glu, and
GABA derived from [2-13C]acetate in diabetic rats remains
unchanged at all carbon sites, and a decreasing trend is ob-
served despite the increase in Gln C4.
Figure 3c shows the specific 13C-enrichment of Asp and
Lac in the C2 and C3 carbons, as well as Suc C2+3 derived
from [2-13C]acetate in the brain of the control and diabetic
groups (1 and 15 weeks of diabetes). The specific 13C-enrich-
ment of these metabolites is significantly higher in 1-week
Fig. 1 Representative 600-MHz 1H NMR spectra of the brain extracts obtained from a control rat (a), a 1-week diabetic rat (b), and a 15-week diabetic
rat (c)
Table 1 Metabolite concentration (mmol/kg) of brain tissue extracts obtained from age-matched control and diabetic 1- and 15-week rats
δ 1H (ppm) Metabolites 1-week 15-week
CON DM DM vs CON (%) CON DM DM vs CON (%)
1.33 Lactate 13.35±1.28 13.92±0.42 104.3 10.04±0.27 10.63±1.25 105.9
1.46 Alanine 0.73±0.05 0.63±0.03 87.21 0.52±0.02 0.60±0.03 115.4
2.01 NAA 7.42±0.06 6.93±0.06 93.35* 7.43±0.04 6.87±0.05 92.50***
2.28 GABA 2.78±0.13 2.53±0.07 91.13 2.78±0.04 2.53±0.12 91.10
2.34 Glutamate 10.37±0.37 10.88±0.12 104.9 10.74±0.12 9.63±0.19 89.74**
2.40 Succinate 1.07±0.11 0.92±0.04 86.06 0.63±0.05 0.68±0.03 108.2
2.46 Glutamine 5.42±0.20 5.18±0.16 95.51 5.97±0.12 5.01±0.09 83.96***
2.82 Aspartate 1.56±0.07 1.40±0.02 89.54 1.47±0.05 1.46±0.03 99.73
3.42 Taurine 5.73±0.15 6.02±0.12 105.1 5.75±0.09 5.83±0.87 101.6
3.53 Myo-inositol 6.26±0.10 6.74±0.19 107.5 5.92±0.07 7.28±0.22 122.9***
Values are expressed as mean±SEM (n=5∼7 for each group)
*p<0.05; **p<0.01; and ***p<0.001 indicate significant differences
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diabetic rats than in the control. By contrast, a significant
decrease in Lac C2 and C3, as well as Suc C2+3 enrichment,
is observed in 15-week diabetic rats compared with the con-
trol. No significant changes in Asp C2 and C3 enrichments are
found.
13C NMR Spectra of [1-13C]Glucose Metabolism
Figure 4a, b illustrates the specific 13C-enrichment of Glu,
Gln, and GABA in the C4, C3, and C2 carbons derived from
[1-13C]glucose. 13C labeling of Glu is more enhanced than
Gln, revealing the predominantly neuronal metabolism of
[1-13C]glucose. In 1-week diabetic rats, the 13C-label incor-
poration into the C4, C3, and C2 positions has remarkably
decreased in Glu and GABA and shown a decreasing trend in
Gln compared with the control. As diabetes developed to
15 weeks, the labeling of Gln, Glu, and GABA in all carbon
positions investigated from [1-13C]glucose has apparently
decreased. In addition, as shown in Fig. 4c, the enrichment
of Asp C3, Lac C3, and Suc C2+3 from [1-13C]glucose has
largely decreased in 1-week diabetic rats and more dramati-
cally reduced in 15-week diabetic rats. However, Lac at the C2
position is unchanged in 1- and 15-week diabetic rats.
The ratio between the carbon flux through pyruvate car-
boxylase (PC) and PDH activities is conventionally deter-
mined on the basis of the (C2-C3)/C4 13C ratios in Glu or
Gln from [1-13C]glucose [29]. As shown in Fig. 5, the Glu and
Gln PC/PDH ratios calculated for the 1-week diabetic group
are not apparently different from those obtained for the control
group. However, the 15-week diabetic group exhibits a clear
increase in the Gln PC/PDH ratio.
Discussion
Diabetes is a complex metabolic disorder that extensively
affects multiple organs and tissues throughout the body. Its
complications are the leading causes of morbidity and mortal-
ity among diabetic patients. The effect of diabetes on the
central nervous system has gained considerable attention; this
effect is characterized by cognitive dysfunction and cerebral
neurophysiological changes [30]. Multiple studies have
shown that the relative risk of developing dementia increases
in diabetic patients [31]. Moreover, the possibility of comor-
bid depression is twice higher in the presence of diabetes [32].
In this study, the 1H NMR-based metabonomics and 13C
Fig. 2 Representative 13C NMR spectra of the brain extracts obtained from the a control rat infused with unlabeled acetate, b control rat, and c 1-week
diabetic rat infused with [2-13C]acetate
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NMR with in vivo injection of 13C-labeled substrates are
applied to the brain extracts of 1- and 15-week diabetic rats.
The global metabolic networks related to glycolysis, TCA
cycle, and specific metabolic pathways, such as PC, pyruvate
recycling, and Glu–Gln–GABA cycle, have been determined.
Effects of Diabetes on Cerebral Nutrient Transport
Glucose is the major energy substrate for brain function under
normal conditions. [1-13C]glucose is metabolized to
[3-13C]pyruvate via glycolysis and then converted to
C4 C3 C2 C4 C3 C2 C2 C3 C4
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Fig. 3 a–c Changes in the
percentages of the 13C-
enrichments in the specific carbon
positions of the metabolites
derived from [2-13C]acetate. The
percentages are calculated from
the 13C NMR spectra of the brain
extracts from 1- and 15-week
diabetic rats compared with that
of the control rats. Significant
differences are assigned as
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[3-13C]lactate by LDH and [3-13C]alanine by alanine amino-
transferase or introduced to the TCA cycle via PC and PDH.
The PC and PDH pathway, respectively, result in the specific
labeling of TCA cycle-derived Glu and Gln. In this study, the
13C-enrichment of [3-13C]lactate has decreased in 1- and 15-
week diabetic rats. This decrease agrees well with the de-
creased LDH activity reported in a previous study [15]. In
addition, the lower 13C incorporation into the cerebral Gln,
Glu, GABA, and Asp after [1-13C]glucose infusion indicates a
decreased mitochondrial pyruvate utilization and neuronal
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TCA cycle activity in 1- and 15-week diabetic rats. Lapidot
and Haber have showed that the lower enrichments of the
cerebral glucose metabolites in diabetic fetal brain may be
attributed not only to endogenous glucose dilution but also to
the fetal brain utilization of a non-labeled carbon source β-
hydroxybutyrate in severe diabetes cases [33]. A decrease in
glucose metabolism may result from neuronal damage or
increased utilization of other energy substrates, such as
MCAs. Besides, such decrease may protect the brain against
the effects of hyperglycemia [34].
In 1-week diabetic rats, the enrichment of Gln C4, Glu C4,
GABA C2, Asp C2, and Asp C3 from [2-13C]acetate has
increased, implying more active astrocytic TCA cycle activity
and acetate utilization. This result is consistent with a previous
observation of the increased brain MCA transport activity in
patients with well-controlled type 1 diabetes [23], which can
possibly lead to decreased glucose utilization.
As an important intermediate product of the TCA cycle, Suc
is an indicator of energymetabolism andmitochondrial function
or activity. After [1-13C]glucose infusion, the enrichment of Suc
C2+3 decreases in 1- and 15-week diabetic rats, suggesting an
impairment in neuronal mitochondrial function. This is consis-
tent with another study that chronic hyperglycemia damages
mitochondrial function, which can directly injure the neuronal
cells in STZ-diabetic rats [35]. The 13C-enrichment of Suc
increases in 1-week diabetic rats but decreases in 15-week
diabetic rats after [2-13C]acetate infusion. This indicates that
the astrocytic mitochondrial function is enhanced in the brain
of 1-week diabetic rats but impaired in 15-week diabetic rats.
Alteration in Neuronal and AstrocyticMarkers in Diabetic Rat
Brain
The concentration of the neuronal marker NAA, which is
synthesized primarily in the mitochondria [36], decreased in
1- and 15-week diabetic rats. This result is closely related to
the neuronal dysfunction or loss in neuronal density in dia-
betic rat brains and consistent with a relative reduction of the
NAA level in the gray matter of T1DM patients based on
in vivo 1H MRS [37]. M-Ins is localized in glial cells and is a
membrane constituent that reflects the proliferation or activa-
tion of glia. This compound can possibly stabilize the intra-
cellular environment [38]. The concomitant increases of m-Ins
and Tau in 15-week diabetic rats suggest that glial prolifera-
tion is a cerebral pathological feature of 15-week diabetic rats.
The high expression of GFAP, a structural and functional
astroglial marker [39], results in an increase in astroglial
reactivity, which is related to diabetic complications [40]. In
addition, neurons are more susceptible to external stimulation
and suppression than glial cells [12, 41]. Such glial prolifera-
tion is most likely an indicator of neuronal damage. This
matches well to a study of human astrocytes express plasmin-
ogen activator inhibitor-1 and protease nexin-1, where astro-
cytic expression has been found to be dynamically regulated
by injury-related factors [42].
Pyruvate Recycling in Diabetic Rat Brain
Pyruvate recycling is a metabolic pathway in the brain, which
was first reported in 1990 using in vivo 13C NMR method
[43]. Subsequent metabolism studies have confirmed that the
pyruvate recycling pathway primarily operates in the glial
compartment [44]. Consistently, we have found that Lac C2
and Lac C3 carbons are labeled equally from [2-13C]acetate
(astrocyte-specific substrate) infusion. This labeling pattern
indicates the presence of the pyruvate recycling pathway in
glial cells. By contrast, [1-13C]glucose heavily labels the Lac
at C3 position, suggesting that the [1-13C]glucose primarily
metabolizes through glycolysis. The physiological signifi-
cance of pyruvate recycling is not completely understood.
Several studies have shown a neuroprotective effect of pyru-
vate or lactate administration [45, 46]. Taking together, we
hypothesize that the synthesized pyruvate can transfer from
astrocytes to neurons in the form of Lac, enter the neuronal
TCA cycle, and provide the neurons with a substrate for
energy metabolism. The present study proposes the enhanced
pyruvate recycling pathway as a protectivemechanism against
metabolic impairments in 1-week diabetic rats.
Neuronal–Glial Interaction in Diabetic Rat Brain
Glu is released by neurons, dispersed from the synaptic cleft,
absorbed by astrocytes via Glu transporters, and then convert-
ed into Gln by the astrocyte-specific enzyme GS. Thereafter,
Gln may be released in the neurons and then re-converted to
Glu by the enzyme phosphate-activated glutaminase. In
GABAergic neurons, Glu can be converted to GABA by
glutamic acid decarboxylase. These interactions between
Glu Gln Glu Gln
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Fig. 5 PC/PDH ratios for Glu and Gln in the brains of 1- and 15-week
diabetic rats compared with those of the age-matched rats. Significant
differences are assigned as follows: ***p<0.001
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neurons and astrocytes are referred as the Gln–Glu–GABA
cycle, which are critical pathways for the neurotransmitters
between astrocytes and neurons. The balance between the
excitatory (Glu) and inhibitory (GABA) processes was altered
in 1-week diabetic rats. The decreased 13C-enrichments of Glu
and GABA in all carbon positions and the increased ratio of
Glu C4/GABA C2 and Glu C2/GABA C4 from [1-13C]glu-
cose infusion are possibly due to the decreased conversion of
Glu to GABA or increased GABA degradation in neurons.
Similar experiments using [2-13C]acetate have shown an in-
crease in the enrichments of Gln C4, Glu C4, and GABA C2
in 1-week diabetic rats. This pattern is consistent with the
increased astrocytic mitochondrial metabolic activity and thus
suggests a better preservation mechanism for the Glu forma-
tion from astrocytic Gln than neuronal Glu synthesis. A study
in diabetic Wistar rats after 10 days of induction has revealed
an enhanced astroglial metabolism to sustain glutamatergic
and GABAergic neurotransmissions [47]. In addition, the
relative 13C-enrichments in Glu compared with Gln signifi-
cantly decrease at the C4 and C2 positions. Moreover, the
decrease in Glu C4/GABAC2 is presumably resulted from the
relative decrease in the transport and utilization of Gln from
astrocytes to glutamatergic and GABAergic neurons. The
limited use of astrocytic precursors by glutamatergic or
GABAergic neurons is indicative of energy metabolism dis-
orders and neuronal death [48].
As diabetes developed to 15 weeks, the concentration of
Glu and Gln has significantly decreased. The [1-13C]glucose
infusions decrease the 13C incorporation of the cerebral Glu
and Gln. The label in Gln C4 is the sum of the astrocytic de
novo synthesis and Glu C4 from neurons. The increased ratios
of Glu C4/Gln C4 can be attributed to the reduced de novo
synthesis of Gln in glial cells and/or decreased Glu uptake by
astrocytes. The increased labeling of Gln C4 but unchanged
Glu C4 from [2-13C]acetate in 15-week diabetic rats indicates
a decrease in the transfer of Gln to neurons. The increase in the
Gln PC/PDH ratios but unchanged Glu PC/PDH ratios in 15-
week diabetic rats confirms that the transport of Gln to Glu
neurons is inhibited. A study using in vivo microdialysis has
reported a reduced neurotransmitter synthesis and a release in
diabetic hippocampus [19]. Therefore, these results reveal the
disordered metabolic trafficking between the astrocytes and
glutamatergic neurons in 15-week diabetic rats.
Conclusions
We have successfully utilized ex vivo high-resolution NMR
technology and [1-13C]glucose and [2-13C]acetate infusion to
investigate the changes in cerebral energy metabolism during
development of diabetes. The study uncovers altered meta-
bolic pathways, such as the enhanced pyruvate recycling
pathway as a protective mechanism against metabolic impair-
ments in 1-week diabetic rats but weakened in 15-week dia-
betic rats. Our results reveal the changes in neuronal–glial
interaction as diabetes developed and thus provide novel
insights into the functions of astrocytes in maintaining normal
neuronal activity at the early stage of diabetes. However,
astrocytes could also damage the metabolic cycle with the
development of diabetes. These results contribute to the un-
derstanding of the underlying mechanism that leads to brain
damage in diabetes.
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